Drug Trial Radar · NCT06554522
Pragmatic Evaluation of Respiratory Distress Syndrome Treatment in Africa
Last checked: Nov 20, 2026Latest source record: Mar 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,512
Planned (sponsor's estimate)
Start
Jan 1, 2025
Primary completion
Sep 30, 2027
Study completion Dec 30, 2027
Sponsor
- Lead sponsor
- Indiana UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Coefficient Giving
- First posted
- Aug 15, 2024
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 1 hour, up to 24 hours
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this pragmatic clinical trial is to learn if the drug surfactant given by a less invasive technique works to treat respiratory distress in preterm infants in low- and middle-income African countries where invasive ventilators are unavailable. It will also learn about the safety of the less invasive surfactant administration (LISA) technique. The main questions it aims to answer are: Does surfactant given by a less invasive surfactant administration technique improve survival in preterm infants in low- and middle-income countries? What medical problems do participants have when receiving surfactant given by the less invasive surfactant administration technique? Researchers will implement the less invasive surfactant administration technique and see if it works to treat respiratory distress in preterm infants compared to preterm who did not receive surfactant. Participants with respiratory distress who are being treated with continuous positive airway pressure and caffeine citrate will: Receive surfactant replacement therapy by the less invasive surfactant administration technique. Be monitored for complications Be followed throughout their hospitalization to determine their survival rate.
Conditions
- Respiratory Distress Syndrome in Premature Infant
- RDS of Prematurity
- Surfactant Deficiency Syndrome Neonatal
- Premature Birth
Interventions
SurfactantDrug
Surfactant is instilled into the lungs through a thin catheter passed into the trachea during laryngoscopy while on continuous positive airway pressure (CPAP)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Hospital SurvivalTime frame: Through hospitalization, an average of 6 months
Locations
8 sites in 4 countries. Site status is shown where the registry gives one.
Centre Hospitalier Universitaire Communautaire
Bangui, Central African Republic · Not yet recruiting
Korle-Bu Teaching Hospital
Accra, Ghana · Not yet recruiting
Komfo Anokye Teaching Hospital
Kumasi, Ghana · Not yet recruiting
Tamale Teaching Hospital
Tamale, Ghana · Not yet recruiting
Coast General Teaching & Referral Hospital
Mombasa, Kenya · Not yet recruiting
Mama Lucy Kibaki Hospital
Nairobi, Kenya · Not yet recruiting
Federal Teaching Hospital Ido-Ekiti
Ido-Ekiti, Ekiti State, Nigeria · Recruiting
University of Ilorin Teaching Hospital
Ilorin, Kwara State, Nigeria · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.